[go: up one dir, main page]

PL2596784T3 - Kompozycje tapentadolu - Google Patents

Kompozycje tapentadolu

Info

Publication number
PL2596784T3
PL2596784T3 PL13000915T PL13000915T PL2596784T3 PL 2596784 T3 PL2596784 T3 PL 2596784T3 PL 13000915 T PL13000915 T PL 13000915T PL 13000915 T PL13000915 T PL 13000915T PL 2596784 T3 PL2596784 T3 PL 2596784T3
Authority
PL
Poland
Prior art keywords
tapentadol
compositions
tapentadol compositions
Prior art date
Application number
PL13000915T
Other languages
English (en)
Inventor
Ramesh Sesha
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL2596784T3 publication Critical patent/PL2596784T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesive Tapes (AREA)
PL13000915T 2007-11-23 2008-11-21 Kompozycje tapentadolu PL2596784T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US402907P 2007-11-23 2007-11-23

Publications (1)

Publication Number Publication Date
PL2596784T3 true PL2596784T3 (pl) 2017-06-30

Family

ID=40263271

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13000915T PL2596784T3 (pl) 2007-11-23 2008-11-21 Kompozycje tapentadolu

Country Status (25)

Country Link
US (3) US20100297229A1 (pl)
EP (3) EP3170494A3 (pl)
JP (1) JP5774850B2 (pl)
KR (3) KR101607112B1 (pl)
CN (3) CN102065852B (pl)
AU (1) AU2008328548B2 (pl)
BR (1) BRPI0819451A2 (pl)
CA (1) CA2706596A1 (pl)
CY (1) CY1118672T1 (pl)
DK (1) DK2596784T3 (pl)
ES (1) ES2619329T3 (pl)
HK (1) HK1184371A1 (pl)
HR (1) HRP20170424T1 (pl)
HU (1) HUE031931T2 (pl)
IL (1) IL205915A (pl)
LT (1) LT2596784T (pl)
MX (2) MX2010005680A (pl)
NZ (2) NZ586361A (pl)
PL (1) PL2596784T3 (pl)
PT (1) PT2596784T (pl)
RS (1) RS55769B1 (pl)
RU (1) RU2497512C2 (pl)
SI (1) SI2596784T1 (pl)
WO (1) WO2009067703A2 (pl)
ZA (1) ZA201003716B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
HUE031931T2 (en) * 2007-11-23 2017-08-28 Gruenenthal Gmbh Tapentadol preparations
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP5731387B2 (ja) * 2008-09-05 2015-06-10 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬配合剤
JP5706825B2 (ja) 2008-10-17 2015-04-22 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. フェノール性オピオイドの放出が減弱された医薬組成物
EP3069717A1 (en) * 2009-04-30 2016-09-21 Grünenthal GmbH Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
MX336038B (es) 2010-04-07 2016-01-07 Lupin Ltd Composiciones farmaceuticas de liberacion controlada de tapentadol.
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
WO2011138037A2 (de) * 2010-05-05 2011-11-10 Ratiopharm Gmbh Festes tapentadol in nicht-kristalliner form
EP2582366B1 (en) * 2010-06-15 2015-10-28 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
MX2013000024A (es) 2010-07-06 2013-02-01 Gruenenthal Gmbh Nuevas formas de dosificacion gastrorretentivas.
CN103153971A (zh) * 2010-07-23 2013-06-12 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的盐或共晶体
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
SI2680833T1 (sl) 2011-03-04 2016-06-30 Gruenenthal Gmbh Parenteralno dajanje tapentadola
EP2680834B1 (en) 2011-03-04 2017-10-18 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
EP3287123B1 (en) 2011-03-04 2020-04-22 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
WO2012122422A2 (en) 2011-03-09 2012-09-13 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
RS58064B1 (sr) 2011-04-05 2019-02-28 Gruenenthal Gmbh Tapentadol za sprečavanje hronifikacije bola
DK3272343T3 (da) 2011-04-29 2020-04-27 Gruenenthal Gmbh Tapentadol til hindring og behandling af depression og angst
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX362435B (es) * 2013-08-02 2019-01-17 Laboratorio Raam De Sahuayo S A De C V Novedoso sistema farmaceutico de entrega bifasica para el tratamiento del dolor y la inflamacion.
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
RU2016116271A (ru) * 2013-09-27 2017-11-01 Джонсон энд Джонсон Консьюмер Инк. Композиции с пульсирующим высвобождением, покрытые оболочкой путем прессования
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
RU2545915C1 (ru) * 2014-02-14 2015-04-10 Олег Васильевич Рубальский Способ лечения хронического болевого синдрома
MX2016014738A (es) * 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
CN104188947A (zh) * 2014-08-26 2014-12-10 安徽省逸欣铭医药科技有限公司 盐酸他喷他多与右旋酮洛芬氨丁三醇的复方药物组合物
CN104434881A (zh) * 2014-11-20 2015-03-25 哈尔滨圣吉药业股份有限公司 一种盐酸他喷他多缓释微丸及其制备方法
ES2710299T3 (es) 2015-03-27 2019-04-24 Gruenenthal Gmbh Formulación estable para la administración parenteral de tapentadol
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3302454B1 (en) 2015-05-26 2021-03-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Compositions for use in treating parkinson's disease and related disorders
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
BR112019005439A2 (pt) 2016-09-23 2019-06-18 Gruenenthal Gmbh formulação estável para administração parenteral de tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
EP3846813A4 (en) * 2018-09-07 2022-06-01 Lohocla Research Corporation ANALGESIC COMPOSITIONS
US11918555B2 (en) * 2020-12-16 2024-03-05 New Frontier Labs, Llc Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase D toxin
KR20230131182A (ko) * 2020-12-16 2023-09-12 뉴 프런티어 랩스 엘엘씨 진통 효과를 유도하기 위한 디카르복실산 에스테르
CN116253652A (zh) * 2021-12-09 2023-06-13 武汉思瓴生物科技有限公司 他喷他多的长链脂肪酸酯类衍生物、药学上可接受的盐、药物组合物及制备方法和应用
CO2024013495A1 (es) 2023-10-05 2025-04-07 Laboratorios Silanes S A De C V Tableta multiactivos en el tratamiento y control de dolor severo crónico y método de preparación

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
CA1083044A (en) 1976-05-04 1980-08-05 Stewart Wong Antiarthritic potentiation
US4260629A (en) 1979-10-25 1981-04-07 E. I. Du Pont De Nemours And Company Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4587252A (en) 1984-12-18 1986-05-06 Brighton Pharmaceutical, Inc. Hydrocodone/ibuprofen pharmaceutical compositions and method
US4571400A (en) 1984-12-18 1986-02-18 Belleview Pharmaceutical, Inc. Dihydrocodeine/ibuprofen pharmaceutical compositions and method
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US5071607A (en) 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
DE69215316T2 (de) * 1991-09-06 1997-03-20 Mcneilab Inc Zusammensetzungen, die Tramadol und irgendein Kodein, Oxykoden oder Hydrokoden enthalten, und deren Verwendung
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20060099249A1 (en) * 2002-02-21 2006-05-11 Pawan Seth Modified release formulations of at least one form of tramadol
EP1506174B1 (en) * 2002-05-17 2015-09-30 Taiwanj Pharmaceuticals Co., Ltd. Use of naltrexone for treating kidney and liver damage
PT1839654E (pt) * 2002-11-22 2010-07-06 Gruenenthal Chemie Utilizaã†o de (1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil) fenol para o tratamento de dor inflamatëria
CN1832736A (zh) * 2003-08-05 2006-09-13 兰贝克赛实验室有限公司 加巴喷丁的稳定缓释口服剂型
CA2595470A1 (en) * 2005-01-21 2006-07-27 Pharmanova Inc. Pharmaceutical formulations and methods of use
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
JP2009522294A (ja) * 2005-12-29 2009-06-11 デポメッド， インコーポレイテッド 胃保持型ガバペンチン投薬形態およびその使用方法
KR101517064B1 (ko) * 2006-04-28 2015-04-30 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀 및 ｎｓａｉｄ를 포함하는 약제학적 병용제
US20070254960A1 (en) * 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
AU2007247481B2 (en) * 2006-04-28 2013-02-14 Grunenthal Gmbh Pharmaceutical combination comprising 3- ( 3-Dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
HUE031931T2 (en) * 2007-11-23 2017-08-28 Gruenenthal Gmbh Tapentadol preparations

Also Published As

Publication number Publication date
HK1184371A1 (zh) 2014-01-24
EP3170494A2 (en) 2017-05-24
KR101607112B1 (ko) 2016-03-29
US20170216212A1 (en) 2017-08-03
RS55769B1 (sr) 2017-07-31
LT2596784T (lt) 2017-03-27
KR101784777B1 (ko) 2017-11-06
BRPI0819451A2 (pt) 2017-10-03
CN104958282A (zh) 2015-10-07
NZ601529A (en) 2014-06-27
WO2009067703A2 (en) 2009-05-28
HRP20170424T1 (hr) 2017-06-16
WO2009067703A3 (en) 2009-09-03
HUE031931T2 (en) 2017-08-28
US20100297229A1 (en) 2010-11-25
MX2010005680A (es) 2010-12-21
JP5774850B2 (ja) 2015-09-09
ES2619329T3 (es) 2017-06-26
IL205915A (en) 2015-08-31
KR20100129264A (ko) 2010-12-08
SI2596784T1 (sl) 2017-04-26
IL205915A0 (en) 2010-11-30
AU2008328548B2 (en) 2014-05-15
AU2008328548A1 (en) 2009-05-28
MX360289B (es) 2018-10-29
DK2596784T3 (en) 2017-03-06
ZA201003716B (en) 2011-02-23
RU2497512C2 (ru) 2013-11-10
US20140242169A1 (en) 2014-08-28
KR101972299B1 (ko) 2019-08-16
PT2596784T (pt) 2017-03-29
EP2219633A2 (en) 2010-08-25
CA2706596A1 (en) 2009-05-28
RU2010123346A (ru) 2011-12-27
EP2596784A1 (en) 2013-05-29
JP2011504509A (ja) 2011-02-10
KR20170116178A (ko) 2017-10-18
CY1118672T1 (el) 2017-07-12
NZ586361A (en) 2012-09-28
CN102908339A (zh) 2013-02-06
CN102065852B (zh) 2015-06-17
CN102065852A (zh) 2011-05-18
EP3170494A3 (en) 2017-09-06
CN104958282B (zh) 2018-05-29
KR20160038066A (ko) 2016-04-06
EP2596784B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
HK1184371A1 (zh) 他噴他多組合物
EP2219637A4 (en) AVENANTHRAMIDE COMPOSITIONS
IL199656A0 (en) Tablet-in-tablet compositions
GB0724342D0 (en) Anitbacterial compositions
HUE059171T2 (hu) Kompozíciók
GB0711683D0 (en) Compositions
GB0700534D0 (en) Composition
GB0712024D0 (en) Compositions
SI2154121T1 (sl) Biognojilni sestavek
GB0710888D0 (en) Composition
ZA200908272B (en) Composition
GB0705885D0 (en) Composition
GB0706343D0 (en) Composition
GB0702446D0 (en) Composition
GB0703719D0 (en) Composition
GB0707972D0 (en) Composition
GB0706739D0 (en) Composition
GB0704651D0 (en) Composition
GB0704659D0 (en) Composition
GB0710559D0 (en) Composition
GB0712043D0 (en) Compositions
GB0708492D0 (en) Compositions
GB0711685D0 (en) Compositions
GB0723803D0 (en) Compositions
GB0713261D0 (en) Compositions